Top

Published in:

Open Access 01-12-2016 | Study protocol

Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository

Authors: E. L. Crawford, A. Levin, F. Safi, M. Lu, A. Baugh, X. Zhang, J. Yeo, S. A. Khuder, A. M. Boulos, P. Nana-Sinkam, P. P. Massion, D. A. Arenberg, D. Midthun, P. J. Mazzone, S. D. Nathan, R. Wainz, G. Silvestri, J. Tita, J. C. Willey

Published in: BMC Pulmonary Medicine | Issue 1/2016

Abstract

Background

The Lung Cancer Risk Test (LCRT) trial is a prospective cohort study comparing lung cancer incidence among persons with a positive or negative value for the LCRT, a 15 gene test measured in normal bronchial epithelial cells (NBEC). The purpose of this article is to describe the study design, primary endpoint, and safety; baseline characteristics of enrolled individuals; and establishment of a bio-specimen repository.

Methods/Design

Eligible participants were aged 50–90 years, current or former smokers with 20 pack-years or more cigarette smoking history, free of lung cancer, and willing to undergo bronchoscopic brush biopsy for NBEC sample collection. NBEC, peripheral blood samples, baseline CT, and medical and demographic data were collected from each subject.

Discussion

Over a two-year span (2010–2012), 403 subjects were enrolled at 12 sites. At baseline 384 subjects remained in study and mean age and smoking history were 62.9 years and 50.4 pack-years respectively, with 34 % current smokers. Obstructive lung disease (FEV1/FVC <0.7) was present in 157 (54 %). No severe adverse events were associated with bronchoscopic brushing. An NBEC and matched peripheral blood bio-specimen repository was established.

The demographic composition of the enrolled group is representative of the population for which the LCRT is intended. Specifically, based on baseline population characteristics we expect lung cancer incidence in this cohort to be representative of the population eligible for low-dose Computed Tomography (LDCT) lung cancer screening. Collection of NBEC by bronchial brush biopsy/bronchoscopy was safe and well-tolerated in this population. These findings support the feasibility of testing LCRT clinical utility in this prospective study. If validated, the LCRT has the potential to significantly narrow the population of individuals requiring annual low-dose helical CT screening for early detection of lung cancer and delay the onset of screening for individuals with results indicating low lung cancer risk. For these individuals, the small risk incurred by undergoing once in a lifetime bronchoscopic sample collection for LCRT may be offset by a reduction in their CT-related risks. The LCRT biospecimen repository will enable additional studies of genetic basis for COPD and/or lung cancer risk.

Trial registration

The LCRT Study, NCT 01130285, was registered with Clinicaltrials.gov on May 24, 2010.

Available only for authorised users

(2014) Cancer Facts & Figures. American Cancer Society. www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf

Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med. 2013;159:411–20.CrossRefPubMed

Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRefPubMed

Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307:2418–29.PubMedCentralCrossRefPubMed

Blomquist T, Crawford EL, Mullins D, Yoon Y, Hernandez DA, Khuder S, et al. Pattern of Antioxidant and DNA Repair Gene Expression in Normal Airway Epithelium Associated with Lung Cancer Diagnosis. Cancer Res. 2009;69:8629–35.PubMedCentralCrossRefPubMed

Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95:470–8.CrossRefPubMed

Raji OY, Duffy SW, Agbaje OF, Baker SG, Christiani DC, Cassidy A, et al. Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case–control and cohort validation study. Ann Intern Med. 2012;157:242–50.PubMedCentralCrossRefPubMed

Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, et al. Lung Cancer Risk Prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Models and Validation. J Natl Cancer Inst. 2011;103:1058–68.PubMedCentralCrossRefPubMed

Field JK, Baldwin D, Brain K, Devaraj A, Eisen T, Duffy SW, et al. CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. Thorax. 2011;66:736–7.CrossRefPubMed

10.

Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98:270–6.PubMedCentralCrossRefPubMed

11.

Spitz MR, Hong WK, Amos CI, Wu XF, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007;99:715–26.CrossRefPubMed

12.

van Klaveren RJ, Habbema JDF, Pedersen JH, de Koning HJ, Oudkerk M, Hoogsteden HC. Lung cancer screening by low-dose spiral computed tomography. Eur Respir J. 2001;18:857–66.CrossRefPubMed

13.

Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369:245–54.PubMedCentralCrossRefPubMed

14.

Birse CE, Lagier RJ, FitzHugh W, Pass HI, Rom WN, Edell ES, et al. Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clin Proteomics. 2015;12:18.PubMedCentralCrossRefPubMed

15.

Pecot CV, Li M, Zhang XJ, Rajanbabu R, Calitri C, Bungum A, et al. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev. 2012;21:786–92.PubMedCentralCrossRefPubMed

16.

Daly S, Rinewalt D, Fhied C, Basu S, Mahon B, Liptay MJ, et al. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol. 2013;8:31–6.CrossRefPubMed

17.

Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Weissfeld JL, et al. Validation of a blood protein signature for non-small cell lung cancer. Clin Proteomics. 2014;11:32.PubMedCentralCrossRefPubMed

18.

Higgins G, Roper KM, Watson IJ, Blackhall FH, Rom WN, Pass HI, et al. Variant Ciz1 is a circulating biomarker for early-stage lung cancer. Proc Natl Acad Sci U S A. 2012;109:E3128–3135.PubMedCentralCrossRefPubMed

19.

Vachani A, Pass HI, Rom WN, Midthun DE, Edell ES, Laviolette M, et al. Validation of a multiprotein plasma classifier to identify benign lung nodules. J Thorac Oncol. 2015;10:629–37.PubMedCentralCrossRefPubMed

20.

Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN, et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol. 2013;8:1156–62.PubMedCentralCrossRefPubMed

21.

Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Nat Acad Sci. 2011;108:3713–8.PubMedCentralCrossRefPubMed

22.

Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med. 2007;13:361–6.CrossRefPubMed

23.

Gower AC, Steiling K, Brothers 2nd JF, Lenburg ME, Spira A. Transcriptomic studies of the airway field of injury associated with smoking-related lung disease. Proc Am Thorac Soc. 2011;8:173–9.PubMedCentralCrossRefPubMed

24.

Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, et al. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. N Engl J Med. 2015;373:243–51.CrossRefPubMed

25.

Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, et al. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014;23:6616–33.PubMedCentralCrossRefPubMed

26.

Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nature genetics. 2014;46:736–41.PubMedCentralCrossRefPubMed

27.

Blomquist TM, Crawford EL, Willey JC. Cis-acting genetic variation at an E2F1/YY1 response site and putative p53 site is associated with altered allele-specific expression of ERCC5 (XPG) transcript in normal human bronchial epithelium. Carcinogenesis. 2010;31:1242–50.PubMedCentralCrossRefPubMed

28.

Blomquist TM, Brown RD, Crawford EL, de la Serna I, Williams K, Yoon Y, et al. CEBPG Exhibits Allele-Specific Expression in Human Bronchial Epithelial Cells. Gene Regul Syst Bio. 2013;7:125–38.PubMedCentralCrossRefPubMed

29.

Blomquist TM, Crawford EL, Lovett JL, Yeo J, Stanoszek LM, Levin A, et al. Targeted RNA-sequencing with competitive multiplex-PCR amplicon libraries. PLoS One. 2013;8, e79120.PubMedCentralCrossRefPubMed

30.

Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 2003;163:1475–80.CrossRefPubMed

31.

Schwartz AG. Genetic epidemiology of cigarette smoke-induced lung disease. Proc Am Thorac Soc. 2012;9:22–6.PubMedCentralCrossRefPubMed

32.

de-Torres JP, Wilson DO, Sanchez-Salcedo P, Weissfeld JL, Berto J, Campo A, et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med. 2015;191:285–91.CrossRefPubMed

33.

Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009;34:380–6.CrossRefPubMed

34.

Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol. 1999;149:13–20.CrossRefPubMed

35.

Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. Ann Intern Med. 1987;106:512–8.CrossRefPubMed

36.

Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med. 1986;105:503–7.CrossRefPubMed

37.

Purdue MP, Gold L, Jarvholm B, Alavanja MC, Ward MH, Vermeulen R. Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers. Thorax. 2007;62:51–6.PubMedCentralCrossRefPubMed

38.

Wasswa-Kintu S, Gan WQ, Man SFP, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005;60:570–5.PubMedCentralCrossRefPubMed

39.

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Revised 2015. Global Initiative for Chronic Obstructive Lung Disease (GOLD). www.goldcopd.org.

40.

Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. COmputed tomography screening and lung cancer outcomes. JAMA. 2007;297:953–61.CrossRefPubMed

41.

Crawford EL, Khuder SA, Durham SJ, Frampton M, Utell M, Thilly WG, et al. Normal bronchial epithelial cell expression of glutathione transferase P1, glutathione transferase M3, and glutathione peroxidase is low in subjects with bronchogenic carcinoma. Cancer Res. 2000;60:1609–18.PubMed

42.

Willey JC, Coy E, Brolly C, Utell MJ, Frampton MW, Hammersley J, et al. Xenobiotic metabolism enzyme gene expression in human bronchial epithelial and alveolar macrophage cells. Am J Respir Cell Mol Biol. 1996;14:262–71.CrossRefPubMed

43.

Crawford EL, Blomquist T, Mullins DN, Yoon Y, Hernandez DR, Al-Bagdhadi M, et al. CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions. Carcinogenesis. 2007;28:2552–9.CrossRefPubMed

44.

Willey JC, Coy EL, Frampton MW, Torres A, Apostolakos MJ, Hoehn G, et al. Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am J Respir Cell Mol Biol. 1997;17:114–24.CrossRefPubMed

45.

Romagnoli M, Vachier I, Vignola AM, Godard P, Bousquet J, Chanez P. Safety and cellular assessment of bronchial brushing in airway diseases. Respir Med. 1999;93:461–6.CrossRefPubMed

46.

Lo Tam Loi AT, Hoonhorst SJM, Franciosi L, Bischoff R, Hoffmann RF, Heijink I, et al. Acute and chronic inflammatory responses induced by smoking in individuals susceptible and non-susceptible to development of COPD: from specific disease phenotyping towards novel therapy. Protocol of a cross-sectional study. BMJ Open. 2013;3.

47.

Kim V, Oros M, Durra H, Kelsen S, Aksoy M, Cornwell WD, et al. Chronic Bronchitis and Current Smoking Are Associated with More Goblet Cells in Moderate to Severe COPD and Smokers without Airflow Obstruction. PLoS ONE. 2015;10, e0116108.PubMedCentralCrossRefPubMed

48.

Barnes NC, Saetta M, Rabe KF. Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast. BMC Pulm Med. 2014;14:9.PubMedCentralCrossRefPubMed

49.

Eissa NT, Erzurum SC. Flexible bronchoscopy in molecular biology. Clin Chest Med. 2001;22(343–353):ix.

50.

Asano F, Aoe M, Ohsaki Y, Okada Y, Sasada S, Sato S, et al. Deaths and complications associated with respiratory endoscopy: A survey by the Japan Society for Respiratory Endoscopy in 2010. Respirology. 2012;17:478–85.CrossRefPubMed

51.

Jin F, Mu D, Chu D, Fu E, Xie Y, Liu T. Severe complications of bronchoscopy. Respiration. 2008;76:429–33.CrossRefPubMed

52.

Facciolongo N, Patelli M, Gasparini S, Lazzari Agli L, Salio M, Simonassi C, et al. Incidence of complications in bronchoscopy. Multicentre prospective study of 20,986 bronchoscopies. Monaldi Arch Chest Dis. 2009;71:8–14.PubMed

53.

Fisher DA, Maple JT, Ben-Menachem T, Cash BD, Decker GA, Early DS, et al. Complications of colonoscopy. Gastrointest Endosc. 2011;74:745–52.CrossRefPubMed

54.

Ko CW, Riffle S, Michaels L, Morris C, Holub J, Shapiro JA, et al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon. Clin Gastroenterol Hepatol. 2010;8:166–73.PubMedCentralCrossRefPubMed

55.

Hattotuwa K, Gamble EA, O’Shaughnessy T, Jeffery PK, Barnes NC. Safety of bronchoscopy, biopsy, and bal in research patients with COPD. Chest. 2002;122:1909–12.CrossRefPubMed

56.

Aldrich MC, Munro HM, Mumma M, Grogan EL, Massion PP, Blackwell TS, et al. Chronic obstructive pulmonary disease and subsequent overall and lung cancer mortality in low-income adults. PLoS One. 2015;10, e0121805.PubMedCentralCrossRefPubMed

57.

Barr RG, Herbstman J, Speizer FE, Camargo Jr CA. Validation of self-reported chronic obstructive pulmonary disease in a cohort study of nurses. Am J Epidemiol. 2002;155:965–71.CrossRefPubMed

58.

Eisner MD, Trupin L, Katz PP, Yelin EH, Earnest G, Balmes J, et al. Development and validation of a survey-based COPD severity score. Chest. 2005;127:1890–7.CrossRefPubMed

59.

Straus SE, McAlister FA, Sackett DL, Deeks JJ. Accuracy of history, wheezing, and forced expiratory time in the diagnosis of chronic obstructive pulmonary disease. J Gen Intern Med. 2002;17:684–8.PubMedCentralCrossRefPubMed

60.

Zhai R, Yu X, Shafer A, Wain JC, Christiani DC. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest. 2014;145:346–53.PubMedCentralCrossRefPubMed

Title: Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository
Authors: E. L. Crawford
A. Levin
F. Safi
M. Lu
A. Baugh
X. Zhang
J. Yeo
S. A. Khuder
A. M. Boulos
P. Nana-Sinkam
P. P. Massion
D. A. Arenberg
D. Midthun
P. J. Mazzone
S. D. Nathan
R. Wainz
G. Silvestri
J. Tita
J. C. Willey
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Pulmonary Medicine / Issue 1/2016
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-016-0178-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository

Abstract

Background

Methods/Design

Discussion

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods/Design

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2016

Effects of a 12-month multi-faceted mentoring intervention on knowledge, quality, and usage of spirometry in primary care: a before-and-after study

Burden of asthma with elevated blood eosinophil levels

Clinical, physiologic, and radiographic factors contributing to development of hypoxemia in moderate to severe COPD: a cohort study

Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)

Endobronchial ultrasound in real life: primary diagnosis and mediastinal staging of lung cancer in patients submitted to thoracic surgery

e-Vita: design of an innovative approach to COPD disease management in primary care through eHealth application

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page